Known targets — ChEMBL curated mechanism
TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8
The experimentally established mechanism targets of Vincristine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TUBB4A known ✓ | P04350 | 6/20 | 0.97 |
| ▸ | TUBB known ✓ | P07437 | 6/20 | 0.97 |
| ▸ | TUBA3C known ✓ | P0DPH7 | 6/20 | 0.97 |
| ▸ | TUBA1B known ✓ | P68363 | 6/20 | 0.97 |
| ▸ | TUBA4A known ✓ | P68366 | 6/20 | 0.97 |
| ▸ | TUBB4B known ✓ | P68371 | 6/20 | 0.97 |
| ▸ | TUBB3 known ✓ | Q13509 | 6/20 | 0.97 |
| ▸ | TUBB2A known ✓ | Q13885 | 6/20 | 0.97 |
| ▸ | TUBB8 known ✓ | Q3ZCM7 | 6/20 | 0.97 |
| ▸ | TUBA3E known ✓ | Q6PEY2 | 6/20 | 0.97 |
| ▸ | TUBA1A known ✓ | Q71U36 | 6/20 | 0.97 |
| ▸ | TUBA1C known ✓ | Q9BQE3 | 6/20 | 0.97 |
| ▸ | TUBB6 known ✓ | Q9BUF5 | 6/20 | 0.97 |
| ▸ | TUBB2B known ✓ | Q9BVA1 | 6/20 | 0.97 |
| ▸ | TUBB1 known ✓ | Q9H4B7 | 6/20 | 0.97 |
| ▸ | MAPT | P10636 | 8/20 | 1.00 |
| ▸ | MEN1 | O00255 | 7/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 7/20 | 1.00 |
| ▸ | LMNA | P02545 | 6/20 | 1.00 |
| ▸ | HIF1A | Q16665 | 5/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Vincristine SCHEMBL3998 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4640472 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4709855 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL2946485 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18398051 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL3710 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL29895946 | 1.00 | MAPT (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4742962 | 0.99 | MAPT (0.98) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL18402663 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A | |
| Vincristine SCHEMBL4769981 | 0.98 | LMNA (1.00) | MAPTMEN1KMT2ALMNAHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2025-05-29 | — | — | US | disclosed |
| US-20250049881-A1 | FORMULATIONS OF GUANYLATE CYCLSE C AGONISTS AND METHODS OF USE | JPMORGAN CHASE BANK, N.A. | 2025-02-13 | — | — | US | disclosed |
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2024-11-19 | — | — | US | disclosed |
| EP-4424697-A2 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | Bausch Health Ireland Limited (IE) | 2024-09-04 | — | — | EP | disclosed |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2024-08-29 | — | — | US | disclosed |
| EP-3004138-B1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LTD (IE) | 2024-03-13 | — | — | EP | disclosed |
| EP-4309673-A2 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | Bausch Health Ireland Limited (IE) | 2024-01-24 | — | — | EP | disclosed |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2023-12-05 | — | — | US | disclosed |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | JPMORGAN CHASE BANK, N.A. | 2023-10-26 | — | — | US | disclosed |
| EP-3708179-B1 | FORMULATIONS OF GUANYLATE CYCLASE C AGONISTS AND METHODS OF USE | BAUSCH HEALTH IRELAND LTD (IE) | 2023-10-04 | — | — | EP | disclosed |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-05-03 | — | — | US | disclosed |
| CN-109743875-B | Inhibitors of the MENIN-MLL interaction | 生命医药有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | BAUSCH HEALTH IRELAND LIMITED (IE) | 2022-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12146003-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20230340023-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20250171497-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20220119449-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-20240287137-A1 | ULTRA-PURE AGONISTS OF GUANYLATE CYCLASE C, METHOD OF MAKING AND USING SAME | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-11319346-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
| US-11834521-B2 | Ultra-pure agonists of guanylate cyclase C, method of making and using same | GUCY1A1, GUCY1A2, GUCY1B1 | TUBB4A 3349/4885TUBB 3481/4885TUBA3C 3064/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.